Relay Therapeutics, Inc. Common Stock
RLAY Real Time Price USDRecent trades of RLAY by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Jul. 12, 2023 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RLAY's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
RLAY Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Substituted isoindolines as pi3k-alpha inhibitors Feb. 04, 2025
-
Patent Title: Fgfr inhibitors and methods of making and using the same Nov. 26, 2024
-
Patent Title: Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof Nov. 12, 2024
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Sep. 10, 2024
-
Patent Title: Shp2 phosphatase inhibitors and methods of making and using the same Feb. 06, 2024
-
Patent Title: Fgfr inhibitors and methods of use thereof Oct. 10, 2023
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Dec. 20, 2022
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Mar. 02, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to RLAY
Number of mentions of RLAY in WallStreetBets Daily Discussion
Recent picks made for RLAY stock on CNBC
ETFs with the largest estimated holdings in RLAY
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RLAY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.